# EDGAR Filing Document

**Accession Number:** 0001133416
**File Stem:** 0001133416-25-000047
**Filing Date:** 2025-11
**Character Count:** 7225
**Document Hash:** cc7083e41bb899956b9c90c05fa7f360
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001133416-25-000047.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001133416-25-000047

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251105

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CALLICUTT JACK W
- **CENTRAL INDEX KEY:** 0001266773

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31791
- **FILM NUMBER:** 251462680

**MAIL ADDRESS:**
- **STREET 1:** 75 FIFTH STREET NW STE. 313
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30308
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALECTIN THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001133416
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043562325
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071
- **BUSINESS PHONE:** 678-620-3186

**MAIL ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20010612

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CALLICUTT JACK W<br><sub>(Last) (First) (Middle)</sub><br>C/O GALECTIN THERAPEUTICS INC.<br>4960 PEACHTREE INDUSTRIAL BLVD., STE 240<br><sub>(Street)</sub><br>NORCROSS, GA 30071<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-05 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>GALECTIN THERAPEUTICS INC [ GALT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 200 | A | $1.98 | 7814 | D |  |
| Common stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 200 | D | $6.00 | 7614 | D |  |
| Common stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 200 | A | $1.11 | 7814 | D |  |
| Common stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 200 | D | $6.00 | 7614 | D |  |
| Common stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 200 | A | $1.72 | 7814 | D |  |
| Common stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 200 | D | $6.00 | 7614 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock option (right to buy) | $1.98 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 200 | 0022-06-30<sup>(2)</sup> | 2032-01-24 | Common stock | 200 | $0 | 39586 | D |  |
| Stock option (right to buy) | $1.11 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 200 | 2023-06-30<sup>(3)</sup> | 2034-01-26 | Common stock | 200 | $0 | 39566 | D |  |
| Stock option (right to buy) | $1.72 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 200 | 2024-06-30<sup>(4)</sup> | 2034-01-22 | Common stock | 200 | $0 | 52809 | D |  |

---

### Footnotes:

(1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

(2) The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

(3) The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

(4) The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.

**Signature:** Jack W. Callicutt  
**Date:** 2025-11-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**